microRNAs and their Therapeutic Strategy in Phase I and Phase II Clinical Trials

References

• Zhang P , Wu W , Chen Q , Chen M . Non-coding RNAs and their integrated networks. J. Integr. Bioinform. 16(3), 20190027 (2019).
   PubMed Web of Science ®Google Scholar
• Suzuki HI . Roles of microRNAs in disease biology. JMA J. 6(2), 104–113 (2023).
   PubMedGoogle Scholar
• Starega-Roslan J , Koscianska E , Kozlowski P , Krzyzosiak WJ . The role of the precursor structure in the biogenesis of microRNA. Cell. Mol. Life Sci. 68(17), 2859–2871 (2011).
   PubMed Web of Science ®Google Scholar
• Sheng P , Fields C , Aadland K et al. Dicer cleaves 5′-extended microRNA precursors originating from RNA polymerase II transcription start sites. Nucleic Acids Res. 46(11), 5737–5752 (2018).
   PubMed Web of Science ®Google Scholar
• Xie M , Li M , Vilborg A et al. Mammalian 5′-capped microRNA precursors that generate a single microRNA. Cell 155(7), 1568–1580 (2013).
   PubMed Web of Science ®Google Scholar
• Del Valle-Morales D , Le P , Saviana M et al. The epitranscriptome in miRNAs: crosstalk, detection, and function in cancer. Genes (Basel) 13(7), 1289 (2022).
   PubMed Web of Science ®Google Scholar
• Matsuyama H , Suzuki HI . Systems and synthetic microRNA biology: from biogenesis to disease pathogenesis. Int. J. Mol. Sci. 21(1), 132 (2019).
   PubMed Web of Science ®Google Scholar
• Komatsu S , Kitai H , Suzuki HI . Network regulation of microRNA biogenesis and target interaction. Cells 12(2), 306 (2023).
   PubMed Web of Science ®Google Scholar
• Selvakumar SC , Preethi KA , Sekar D . MicroRNAs as important players in regulating cancer through PTEN/PI3K/AKT signalling pathways. Biochim. Biophys. Acta Rev. Cancer 1878(3), 188904 (2023).
   PubMed Web of Science ®Google Scholar
• Ratti M , Lampis A , Ghidini M et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target. Oncol. 15(3), 261–278 (2020).
   PubMed Web of Science ®Google Scholar
• Sekar D , Selvakumar SC , Auxzilia Preethi K . Therapeutic nature of microRNAs in oral squamous cell carcinoma (OSCC). Oral Oncol. 134, 106106 (2022).
   PubMed Web of Science ®Google Scholar
• Nasimi Shad A , Fanoodi A , Maharati A , Akhlaghipour I , Moghbeli M . Molecular mechanisms of microRNA-301a during tumor progression and metastasis. Pathol. Res. Pract. 247, 154538 (2023).
   PubMed Web of Science ®Google Scholar
• Asl ER , Sarabandi S , Shademan B , Dalvandi K , Sheikhansari G , Nourazarian A . MicroRNA targeting: a novel therapeutic intervention for ovarian cancer. Biochem. Biophys. Rep. 35, 101519 (2023).
   PubMedGoogle Scholar
• Hanna J , Hossain GS , Kocerha J . The potential for microRNA therapeutics and clinical research. Front. Genet. 10, 478 (2019).
   PubMed Web of Science ®Google Scholar
• Chakraborty C , Sharma AR , Sharma G , Lee S-S . Therapeutic advances of miRNAs: a preclinical and clinical update. J. Adv. Res. 28, 127–138 (2021).
   PubMed Web of Science ®Google Scholar
• Yang J . Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev. Clin. Pharmacol. 12(2), 95–99 (2019).
   PubMed Web of Science ®Google Scholar
• siRNA Therapeutics: Current Status andDelivery System. www.biochempeg.com/article/339.html#:~:text=In%20preclinical%20studies%2C%20the%20delivery,siRNA%20conjugates%2C%20and%20so%20on
   Google Scholar
• He B , Zhao Z , Cai Q et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int. J. Biol. Sci. 16(14), 2628–2647 (2020).
   PubMed Web of Science ®Google Scholar
• Reid G , Kao SC , Pavlakis N et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 8(8), 1079–1085 (2016).
   PubMed Web of Science ®Google Scholar
• Casarotto M , Fanetti G , Guerrieri R et al. Beyond microRNAs: emerging role of other non-coding RNAs in HPV-driven cancers. Cancers (Basel) 12(5), 1246 (2020).
   PubMed Web of Science ®Google Scholar
• Lundstrom K . Latest development on RNA-based drugs and vaccines. Futur. Sci. OA 4(5), FSO300 (2018).
   PubMed Web of Science ®Google Scholar
• Sempere LF , Azmi AS , Moore A . microRNA-based diagnostic and therapeutic applications in cancer medicine. Wiley Interdiscip. Rev.RNA 12(6), (2021).
   PubMed Web of Science ®Google Scholar
• Gareev I , Beylerli O , Tamrazov R et al. Methods of miRNA delivery and possibilities of their application in neuro-oncology. Noncoding RNA Res. 8(4), 661–674 (2023).
   PubMed Web of Science ®Google Scholar
• Saiyed AN , Vasavada AR , Johar SRK . Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases. Futur. J. Pharm. Sci. 8(1), 24 (2022).
   PubMed Web of Science ®Google Scholar
• Menon A , Abd-Aziz N , Khalid K , Poh CL , Naidu R . miRNA: a promising therapeutic target in cancer. Int. J. Mol. Sci. 23(19), 11502 (2022).
   PubMed Web of Science ®Google Scholar
• Frydrychowicz M , Kuszel Ł , Dworacki G , Budna-Tukan J . MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy. J. Appl. Genet. 64(3), 459–477 (2023).
   PubMedGoogle Scholar
• Tassone P , Di Martino MT , Arbitrio M et al. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. J. Hematol. Oncol. 16(1), 68 (2023).
   PubMed Web of Science ®Google Scholar
• Cushing L , Kuang PP , Qian J et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45(2), 287–294 (2011).
   PubMed Web of Science ®Google Scholar
• Panigrahi M , Palmer MA , Wilson JA . MicroRNA-122 regulation of HCV infections: insights from studies of miR-122-independent replication. Pathogens 11(9), 1005 (2022).
   PubMed Web of Science ®Google Scholar
• Zheng Q , Reid G , Eccles MR , Stayner C . Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease. Front. Physiol. 13, 1006427 (2022).
   PubMed Web of Science ®Google Scholar
• Hamburg N , Leeper N . Therapeutic potential of modulating microRNA in peripheral artery disease. Curr. Vasc. Pharmacol. 13(3), 316–323 (2015).
   PubMed Web of Science ®Google Scholar
• Iacomino G . miRNAs: the road from bench to bedside. Genes (Basel) 14(2), 314 (2023).
   PubMed Web of Science ®Google Scholar
• Ghosh D , Nandi S , Bhattacharjee S . Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin. Transl. Med. 7(1), 33 (2018).
   PubMedGoogle Scholar
• Varkaris A , Caravan P , Robertson N et al. Abstract CT246: an open-label, single-center, phase 0, microdose study to demonstrate delivery of TTX-MC138-NODAGA-Cu64 to radiographically confirmed metastases in subjects with advanced solid tumors. Cancer Res. 83(Suppl. 8), CT246–CT246 (2023).
   Web of Science ®Google Scholar
• de Gooijer CJ , Baas P , Burgers JA . Current chemotherapy strategies in malignant pleural mesothelioma. Transl. Lung Cancer Res. 7(5), 574–583 (2018).
   PubMed Web of Science ®Google Scholar
• Kim T , Croce CM . MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp. Mol. Med. 55(7), 1314–1321 (2023).
   PubMed Web of Science ®Google Scholar
• Sun L , Yu Y , Niu B , Wang D . Red blood cells as potential repositories of microRNAs in the circulatory system. Front. Genet. 11, 442 (2020).
   PubMed Web of Science ®Google Scholar
• Carrer M , Liu N , Grueter CE et al. Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*. Proc. Natl Acad. Sci. USA 109(38), 15330–15335 (2012).
   PubMed Web of Science ®Google Scholar
• Walayat A , Yang M , Xiao D . Therapeutic implication of miRNA in human disease. In: Antisense Therapy. IntechOpen, London, UK (2019).
   Google Scholar
• Parisi R , Symmons DPM , Griffiths CEM , Ashcroft DM . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133(2), 377–385 (2013).
   PubMed Web of Science ®Google Scholar
• Sassi Y , Avramopoulos P , Ramanujam D et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat. Commun. 8(1), 1614 (2017).
   PubMedGoogle Scholar
• Deng H , Chen Y , Li P et al. PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer. Cancer Pathog. Ther. 1(1), 56–66 (2023).
   PubMedGoogle Scholar
• Hennessy BT , Smith DL , Ram PT , Lu Y , Mills GB . Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4(12), 988–1004 (2005).
   PubMed Web of Science ®Google Scholar
• Aguayo F , Perez-Dominguez F , Osorio JC , Oliva C , Calaf GM . PI3K/AKT/mTOR signaling pathway in HPV-driven head and neck carcinogenesis: therapeutic implications. Biology (Basel) 12(5), 672 (2023).
   PubMedGoogle Scholar
• Jerusalem G , de Boer RH , Hurvitz S et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer. JAMA Oncol. 4(10), 1367 (2018).
   PubMed Web of Science ®Google Scholar
• Bautista-Sánchez D , Arriaga-Canon C , Pedroza-Torres A et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol. Ther. Nucleic Acids 20, 409–420 (2020).
   PubMedGoogle Scholar
• Wang B , Wang H , Yang Z . MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLOS ONE 7(10), e47053 (2012).
   PubMed Web of Science ®Google Scholar
• Junhua Z , Yong C , Xiaomeng L , Gang Z , Zhong L . MiR-122-3p sensitizes breast cancer cells to ionizing radiation via controlling of cell apoptosis, migration and invasion. Int. J. Clin. Exp. Pathol. 10(1), 215–223 (2017).
   Web of Science ®Google Scholar
• Song C , Liu L-Z , Pei X-Q et al. miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget 6(33), 34968–34978 (2015).
   PubMedGoogle Scholar
• Chen Y , Sun Y , Chen L et al. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol. Med. Rep. 7(5), 1579–1584 (2013).
   PubMed Web of Science ®Google Scholar
• Keewan E , Matlawska-Wasowska K . The emerging role of suppressors of cytokine signaling (SOCS) in the development and progression of leukemia. Cancers (Basel) 13(16), 4000 (2021).
   PubMed Web of Science ®Google Scholar
• Pidíková P , Herichová I . miRNA clusters with up-regulated expression in colorectal cancer. Cancers (Basel) 13(12), 2979 (2021).
   PubMed Web of Science ®Google Scholar
• Segal M , Slack FJ . Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opin. Drug Discov. 15(9), 987–992 (2020).
   PubMed Web of Science ®Google Scholar
• Yang H-W , Huang C-Y , Lin C-W et al. Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. Biomaterials 35(24), 6534–6542 (2014).
   PubMed Web of Science ®Google Scholar
• Dasgupta I , Chatterjee A . Recent advances in miRNA delivery systems. Methods Protoc. 4(1), 10 (2021).
   PubMedGoogle Scholar
• Ramaiah MJ . Functions and epigenetic aspects of miR-15/16: possible future cancer therapeutics. Gene Rep. 12, 149–164 (2018).
   Google Scholar
• Höbel S , Aigner A . Polyethylenimines for siRNA and miRNA delivery in vivo . Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5(5), 484–501 (2013).
   PubMed Web of Science ®Google Scholar
• Koenig O , Nothdurft D , Perle N et al. An atelocollagen coating for efficient local gene silencing by using small interfering RNA. Mol. Ther. Nucleic Acids 6, 290–301 (2017).
   PubMedGoogle Scholar
• Öztuna A , Nazır H . In vitro transfection potential of fluorinated G5 PAMAM dendrimers for miRNA delivery to MRC-5 cells. Eur. Res. J. 4(2), 92–100 (2017).
   Google Scholar
• Wang H , Zhao X , Guo C et al. Aptamer–dendrimer bioconjugates for targeted delivery of miR-34a expressing plasmid and antitumor effects in non-small cell lung cancer cells. PLOS ONE 10(9), e0139136 (2015).
   PubMed Web of Science ®Google Scholar
• Leiro V , Garcia JP , Tomás H , Pêgo AP . The present and the future of degradable dendrimers and derivatives in theranostics. Bioconjug. Chem. 26(7), 1182–1197 (2015).
   PubMed Web of Science ®Google Scholar
• Fornari F , Gramantieri L , Callegari E et al. MicroRNAs in animal models of HCC. Cancers (Basel) 11(12), 1906 (2019).
   PubMed Web of Science ®Google Scholar
• Agrawal S , Giri TK , Tripathi DK , Ajazuddin , Alexander A . A review on novel therapeutic strategies for the enhancement of solubility for hydrophobic drugs through lipid and surfactant based self micro emulsifying drug delivery system: a novel approach. Am. J. Drug Discov. Dev. 2(4), 143–183 (2012).
   Google Scholar
• Bajan S , Hutvagner G . RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells 9(1), 137 (2020).
   PubMed Web of Science ®Google Scholar
• Raza F , Evans L , Motallebi M et al. Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomater. 157, 1–23 (2023).
   PubMed Web of Science ®Google Scholar
• Forterre A , Komuro H , Aminova S , Harada M . A comprehensive review of cancer microRNA therapeutic delivery strategies. Cancers (Basel) 12(7), 1852 (2020).
   PubMed Web of Science ®Google Scholar
• Stenvang J , Petri A , Lindow M , Obad S , Kauppinen S . Inhibition of microRNA function by antimiR oligonucleotides. Silence 3(1), 1 (2012).
   PubMedGoogle Scholar
• Segal M , Biscans A , Gilles M-E et al. Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 In Vivo . Mol. Ther. Nucleic Acids 19, 267–277 (2020).
   PubMedGoogle Scholar
• Lennox KA , Behlke MA . Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18(12), 1111–1120 (2011).
   PubMed Web of Science ®Google Scholar
• Bilensoy E . Cationic nanoparticles for cancer therapy. Expert Opin. Drug Deliv. 7(7), 795–809 (2010).
   PubMed Web of Science ®Google Scholar
• Yu H-R , Huang L-H , Li S-C . Roles of microRNA in the immature immune system of neonates. Cancer Lett. 433, 99–106 (2018).
   PubMed Web of Science ®Google Scholar
• Navickas R , Gal D , Laucevičius A , Taparauskaitė A , Zdanytė M , Holvoet P . Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc. Res. 111(4), 322–337 (2016).
   PubMed Web of Science ®Google Scholar
• Pagoni M , Cava C , Sideris DC et al. miRNA-based technologies in cancer therapy. J. Pers. Med. 13(11), 1586 (2023).
   PubMed Web of Science ®Google Scholar